Proof‐of‐Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase‐4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2014 (1) , 682014
Abstract
Introduction. Converging evidence suggests that PDE‐4 (phosphodiesterase subtype 4) plays a crucial role in regulating cognition via the PDE‐4‐cAMP cascade signaling involving phosphorylated cAMP response element binding protein (CREB). Objective. The primary endpoint was to examine the neurocognitive effects of extract Sceletium tortuosum (Zembrin) and to assess the safety and tolerability of Zembrin in cognitively healthy control subjects. Method. We chose the randomized double‐blind placebo‐controlled cross‐over design in our study. We randomized normal healthy subjects (total n = 21) to receive either 25 mg capsule Zembrin or placebo capsule once daily for 3 weeks, in a randomized placebo‐controlled 3‐week cross‐over design. We administered battery of neuropsychological tests: CNS Vital Signs and Hamilton depression rating scale (HAM‐D) at baseline and regular intervals and monitored side effects with treatment emergent adverse events scale. Results. 21 subjects (mean age: 54.6 years ± 6.0 yrs; male/female ratio: 9/12) entered the study. Zembrin at 25 mg daily dosage significantly improved cognitive set flexibility (P < 0.032) and executive function (P < 0.022), compared with the placebo group. Positive changes in mood and sleep were found. Zembrin was well tolerated. Conclusion. The promising cognitive enhancing effects of Zembrin likely implicate the PDE‐4‐cAMP‐CREB cascade, a novel drug target in the potential treatment of early Alzheimer’s dementia. This trial is registered with ClinicalTrials.gov NCT01805518.Keywords
Funding Information
- HG&H Pharmaceuticals (Pty) Ltd.
This publication has 40 references indexed in Scilit:
- Executive functions in clinical and preclinical Alzheimer's diseaseRevue Neurologique, 2013
- Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive declineBrain Research, 2013
- Serotonin and decision making processesNeuroscience & Biobehavioral Reviews, 2012
- Executive deficits are related to the inferior frontal junction in early dementiaBrain, 2011
- Changes in cognitionNeurobiology of Aging, 2011
- Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP SignalingJournal of Neuroscience, 2011
- Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safetyNature Biotechnology, 2010
- Sceletium—A review updateJournal of Ethnopharmacology, 2008
- Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaquesPsychopharmacology, 2007
- Reliability and validity of a computerized neurocognitive test battery, CNS Vital SignsArchives of Clinical Neuropsychology, 2006